Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

Summary

Treatment with olutasidenib for isocitrate dehydrogenase 1 (IDH1) mutant acute myeloid leukemia (AML) after completion of traditional intensive induction/consolidation is likely to be safe, tolerable, and may provide clinical benefit in terms of maintenance of remission and perhaps improvement in survival.

Timeline

Start

2026-02-02

Primary completion

2028-10-31

Completion

2030-10-31

Drugs

Indications